The past decade of research on hypoxic responses has provided a considerable understanding of how cells respond to hypoxic stress at the molecular level, thanks to the identification and molecular cloning of the hypoxia-inducible transcription factor, HIF-1a. Numerous target genes have since been identified to account for various aspects of the hypoxic response, including angiogenesis and glycolysis. Yet, fundamental questions remain regarding the mechanisms by which hypoxia controls cell proliferation, genetic instability, mitochondrial biogenesis, and oxidative respiration in cancer cells. Although the protooncoprotein c-Myc appears to be the diametrical opposite of HIF-1a in most of these processes, recent studies indicate that c-Myc is an integral part of the HIF-a-c-Myc molecular pathway in the hypoxic response. It has been shown that HIF-a engages with Myc by various mechanisms to achieve oxygen homeostasis for cell survival. This article focuses on the intricate roles of cMyc in the hypoxic response, discusses various mechanisms controlling c-Myc activity by HIF-a for the regulation of hypoxiaresponsive genes, and emphasizing the outcome of gene expression apparently dependent upon hypoxic conditions, cellular context, and gene promoter.
Solid tumors tend to develop hypoxia (oxygen deprivation), which arises out of the rapid cell proliferation that outstrips the supply of oxygen from the blood vessels. Consequently, tumor hypoxia activates hypoxia-inducible factor (HIF)-1a and HIF-2a, 1 ,2 two of the well-characterized hypoxia-inducible transcription factors critical for tumor angiogenesis, glycolysis, and metastasis. [3] [4] [5] Under physiological conditions, hypoxia activates the ubiquitous HIF-1a, whereas HIF-2a expression is more tissue specific. Yet in human cancers of diverse origins, both HIF-1a and HIF-2a, referred to collectively hereinafter as HIF-a, are frequently overexpressed and activated.
Hypoxia-inducible factor-a is the regulatory subunit of the HIF heterodimeric complex paired with the aryl hydrocarbon receptor nuclear translocator (ARNT, also known as HIF-1b). 6 They belong to the Per-ARNT-Sim (PAS) superfamily 7 of transcription factors containing basic helix-loop-helix domains ( Figure 1a ). Whereas PAS domains confer target gene specificity through protein-protein interactions, 8 the oxygendependent degradation domain, unique to HIF-a, mediates oxygen-dependent proteolysis. 9 As such, despite constitutive transcription and translation of the HIF1A and EPAS1 genes (encoding HIF-1a and HIF-2a, respectively), HIF-a protein levels remain low in oxygenated conditions because of proteolysis via the ubiquitin-proteasome pathway. [9] [10] [11] [12] HIF-a degradation requires the pVHL-containing E3 ubiquitin ligase, [13] [14] [15] which recognizes two hydroxylated proline residues of HIF-a (P402 and P564 in HIF-1a; Figure 1a) . [16] [17] [18] HIFa is hydroxylated by three prolyl hydroxylases, EglN1, EglN2, and EglN3 (better known as PHD2, PHD1, and PHD3, respectively), which sense oxygen tension and transduce oxygen signals through hydroxylation. [19] [20] [21] Interestingly, HIF1a is also subjected to asparaginyl hydroxylation at N803 (Figure 1a) , which is located in the C-terminal transactivation domain that recruits the transcription co-activator p300/ CBP. 22 Thus, the asparaginyl hydroxylation hinders p300/ CBP binding, thereby inhibiting HIF-a transactivation. [23] [24] [25] By contrast, hypoxia inhibits hydroxylation by limiting oxygen availability, resulting in HIF-a stabilization, which triggers the HIF-a activation cascade involving dimerization with ARNT, recruitment of p300/CBP, and binding to the hypoxia-responsive element (HRE) in the promoter of hypoxiaresponsive genes for transcriptional activation (Figure 1b) . 4 These remarkable advances have smoothed the way for the identification of an ever-expanding body of hypoxiaresponsive genes that account for many aspects of tumor hypoxia, including angiogenesis, glycolysis, low pH, and cell survival. Yet, unanswered questions remain regarding how hypoxia alters cell proliferation, induces genetic instability, and reprograms cell metabolism and mitochondrial biogenesis, which are critical for tumor survival and progression. Recent studies, however, have begun to shed new light on these questions by unraveling the intricate role of the protooncoprotein c-Myc in relation to HIF-a in adaptation to the tumor microenvironment. [26] [27] [28] [29] c-Myc plays a central role in a transcription factor network that regulates cellular growth, differentiation, apoptosis, and metabolism. 30, 31 It is frequently overexpressed in human cancers because of genetic rearrangements such as gene amplifications and chromosomal translocation. Deregulated c-Myc expression has been shown to drive vasculogenesis, reduce cell adhesion, and promote metastasis. 32 c-Myc can activate and repress transcription of its target genes. When in a binary complex with its partner Max, it activates transcription by binding to an E-box consensus sequence. However, Max also pairs with the c-Myc antagonist Mad1 or Max interactor 1 (Mxi1) to occupy the same E-box element for gene repression. In addition, the c-Myc-Max can be recruited by Miz1 for gene repression to core promoter sequences that lack the E-box sequence. Other transcription factors including Sp1 can also tether c-Myc to core promoter sequences. 32 Although HIF-a and c-Myc share common target genes, such as those involved in glycolysis and angiogenesis, they apparently have opposing effects on cell proliferation, mitochondrial biogenesis, and DNA repair. How both HIF-1a and HIF-2a employ diverse mechanisms by either collaborating with or counteracting c-Myc to mediate adaptive responses to hypoxia, why HIF-1a differs functionally from HIF-2a in engaging with c-Myc, and how HIF-1a and HIF-2a sometimes have opposite effects on c-Myc are discussed below. These interesting yet complex findings suggest that target gene promoter, cellular context, and hypoxic environment determine the way by which HIF-a engages with c-Myc and consequently the outcome of target gene expression.
HIF-1a Regulates Cell Cycle and DNA Repair Genes by Counteracting c-Myc Activities Through c-Myc Displacement
The c-Myc ternary repressive complex containing Miz1 is known to repress the cyclin-dependent kinase inhibitor gene CDKN1A (encoding p21 cip1 ) for cell-cycle progression. 33, 34 By contrast, hypoxia upregulates CDKN1A gene in an HIF-1a-dependent way. 35, 36 Furthermore, HIF-1a expression is sufficient to stimulate CDKN1A expression in normoxia, leading to cell-cycle arrest. 26, 37 Of particular interest is that such gene upregulation, in contrast with the HIF-a activation cascade (Figure 1b) , is independent of HIF-1a DNA-binding and transactivation domains. 26 In fact, the N-terminal portion of HIF-1a that harbors PAS domains ( Figure 1a ) is sufficient to induce CDKN1A expression and cell-cycle arrest, suggesting alternative mechanisms for HIF-1a activation of the CDKN1A gene. Indeed, HIF-1a activates CDKN1A gene expression by displacing the inhibitory c-Myc from binding to the CDKN1A proximal promoter, resulting in gene derepression ( Figure 2a ). Likewise, another cyclin-dependent kinase inhibitor gene CDKN1B (encoding p27 kip1 ), also suppressed by c-Myc, can be upregulated by hypoxia by a similar mechanism. 28, 37 Thus, HIF-1a antagonizes repressive c-Myc activity for gene activation. It should be noted that unlike c-Myc displacement from the MSH2 promoter (see below), the biochemistry of c-Myc displacement by HIF-1a in the CDKN1A and CDKN1B gene promoters has not been well characterized.
In the absence of Miz1, c-Myc forms an activating complex with Max for gene activation. 38 Would HIF-1a counteract an activating c-Myc, thereby resulting in gene repression? Very few genes have been reported to be downregulated by hypoxia, and the underlying mechanisms hitherto have been elusive. Evidently, hypoxia-induced gene repression can hardly be explained by the direct role of HIF-1a in transcriptional activation through binding to the HRE (Figure 1b) . However, several studies have shown that c-Myc displacement accounts for hypoxic repression of c-Myc-activated 
A more intriguing question, however, is how HIF-1a displaces an activating c-Myc from the target gene promoter. As for the CDKN1A upregulation, HIF-1a uses its N-terminal portion, the PAS-B subdomain (Figure 1a ) in particular, for gene repression. 27, 39 HIF-1a competes with c-Myc for binding to the transcription factor Sp1 that directly interacts with the MSH2 promoter. Such competition is consistent with a tenuous interaction between HIF-1a and c-Myc in the cytosol. 26 Accordingly, c-Myc interacts with Sp1 for gene activation in normoxia where HIF-1a levels are low. Under hypoxia, HIF-1a occupies Sp1 via c-Myc displacement, resulting in gene inactivation (Figure 2b) .
The requirement of Sp1 for c-Myc displacement raises the question as to whether c-Myc displacement occurs when c-Myc is bound directly to an E-box element. Interestingly, although both NBS1 and CDC25A genes harbor an E-box element in their introns, no significant changes in c-Myc binding to the E-box have been detected when gene expression is suppressed. 39, 40 Therefore, it appears that HIF-1a selectively targets c-Myc bound indirectly to DNA via another transcription factor for displacement (Figure 2b) . Such a selective mechanism may explain the relatively weak suppression (approximately two-to threefold) of these genes by hypoxia, because of the remnant c-Myc-activating activity bound to the E-box. Furthermore, it stands to reason that HIF-1a might displace c-Myc from Sp1 more readily than from an E-box element, assuming a stronger binding affinity to the DNA sequence. However, more quantitative analyses of c-Myc binding to the E-box element in c-Myc-activated genes such as ODC, CCND2, and E2F1 (encoding ornithine decarboxylase 1, cyclin D2, and E2F transcription factor 1, respectively) have shown decreased c-Myc promoter occupancy under hypoxia, 28 suggesting the occurrence of c-Myc displacement from the E-box element, albeit to a lesser extent. Furthermore, HIF-1a also induces a shift in the heterocomplex formation from activating c-Myc-Max to repressive Mad1-Max or Mxi1-Max, thereby further contributing to the inactivation of c-Myc target genes.
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HIF-2a, in Contrast with HIF-1a, Promotes Cell Proliferation by Enhancing c-Myc Activities Through Stimulation of Max Binding
Although both HIF-1a and HIF-2a follow the same HIF-a activation cascade (Figure 1b) for gene activation, studies have shown that HIF-2a possesses divergent (patho)physiological functions despite striking similarities to HIF-1a in amino-acid sequence and protein structure. [42] [43] [44] [45] [46] [47] At the molecular level, several HIF-2a preferentially regulated genes have been identified, including CCND1, EPO, POU5F1, TGFA, and VEGFA (encoding cyclin D1, erythropoietin, octamer-binding transcription factor 4, transforming growth factor a, vascular endothelial growth factor A, respectively). 46, 48, 49 However, how HIF-2a specifically targets these genes remains unclear, although the involvement of ETS transcription factors in HIF-2a target gene selection has been suggested. 50 Thus, given the high percentage of identity in amino-acid sequence particularly to the HIF-1a PAS-B domain, does HIF-2a also engage in c-Myc displacement? Interestingly, HIF-2a is not involved in the c-Myc counteraction because of its inability to compete with c-Myc for Sp1 binding. 39 Accordingly, HIF-2a fails to repress any of the foregoing DNA repair genes. 27, 39 What distinguishes HIF-2a from HIF-1a in c-Myc displacement is a specific phosphorylation of HIF-2a at codon T324 (equivalent to HIF-1a T322; Figure 1a ) by protein kinase D1, which prevents HIF-2a from competing for Sp1 binding. Conversely, HIF-1a, which is not subjected to phosphorylation at T322, is capable of c-Myc displacement.
Interestingly, what is remarkable is not what HIF-2a cannot do, but what it can. It has been uncovered that HIF-2a's 'hidden talent' is to enhance c-Myc activities by stimulating the interaction with Max. 28 As a result, HIF-2a promotes, rather than inhibits, cell-cycle progression in hypoxic cells by further inhibiting the expression of cyclin-dependent kinase inhibitor genes CDKN1A and CDKN1B (Figure 3a) and by augmenting the expression of cell-cycle genes CCND2 and E2F1 (Figure 3b) . Moreover, the effects of HIF-2a on gene expression correlate with increased c-Myc target-gene promoter occupancy in hypoxic cells, and HIF-2a facilitates formation of c-Myc-Max complex through binding to Max. Evidently, further molecular and biochemical characterization of HIF-2a interactions with Max should provide a mechanistic understanding of the functional difference between HIF-1a and HIF-2a in cell-cycle regulation. It will also be interesting to determine whether these opposing effects on cell cycle by HIF-1a and HIF-2a occur in the same tumor cell or if one dominates the other depending on their expression levels.
HIF-a Controls Mitochondrial Biogenesis by Inhibiting c-Myc-Mediated Transcription Through the Induction of c-Myc Degradation and Mxi1 Expression
In contrast with the opposing effects on c-Myc by HIF-1a and HIF-2a, the two HIF-a isoforms have been reported to work in the same direction to inhibit mitochondrial biogenesis. 29 Peroxisome proliferators-activated receptor g coactivator 1b is a transcription factor that is regulated by c-Myc and implicated in mitochondrial biogenesis. Study has shown that HIF-a overexpression in a pVHL-deficient renal carcinoma cell line inhibits PGC-1b expression, resulting in decreased mitochondrial DNA content, mitochondrial mass, and oxygen consumption. 29 Both HIF-1a and HIF-2a are involved in the transcriptional repression of PPARGC1B (encoding PGC-1b). In contrast to the direct role of HIF-1a in c-Myc target gene repression (Figure 2b) , the HIF-a isoforms inhibit PPARGC1B expression in two indirect ways (Figure 4a ). On the one hand, HIF-a transcriptionally activates the MXI1 gene (encoding Mxi1 that competes for Max binding). 29, 41 On the other hand, HIF-a contributes to c-Myc proteolysis under severe or prolonged hypoxia via the ubiquitin-proteasome pathway without affecting MYC mRNA levels. Such a double-punch mechanism of c-Myc inactivation has also been shown to be responsible for transcriptional repression of other c-Myc-activated genes such as CAD (encoding carbamoylphosphate synthetase 2/aspartate trans-carbamylase/dihydroorotase) and ODC1. Therefore, both HIF-a isoforms induce c-Myc degradation and MXI1 gene expression to inhibit c-Myc activity.
Although the contribution of HIF-a to c-Myc degradation is not well understood, the above studies support the notion that c-Myc can be regulated at different levels under different hypoxic conditions and perhaps in different cell types. Treatment with mild hypoxic conditions at 0.5-1% oxygen levels for less than 24 h leads to no significant change in c-Myc protein levels; [26] [27] [28] however, severe hypoxic conditions such as 0.1% oxygen or prolonged treatment result in c-Myc degradation without affecting MYC mRNA levels. 29 , 41 Yet, transcriptional downregulation of MYC gene by hypoxia has also been suggested to be a possible mechanism controlling the expression of AFP gene (encoding a-fetoprotein), 51 which is activated by c-Myc. Furthermore, given MYC gene being a transcriptional target of the b-catenin/T-cell factor-4 complex, such mechanism apparently accounts for the derepression of CDKN1A gene in hypoxic colon cancer cells, where HIF-1a disrupts the complex formation by competing for b-catenin binding, thereby reducing c-Myc levels. 52 Therefore, c-Myc activity can be affected by various hypoxic conditions.
In c-Myc-Deregulated Cells, HIF-1a Cooperates with c-Myc to Enhance Common Target Gene Expression
In human cancers, c-Myc deregulation is mostly a result of genetic rearrangements that disable homeostatic mechanisms controlling c-Myc protein levels. Thus, c-Myc may no longer be subjected to hypoxic regulation as discussed above. It has been shown that in a Burkitt lymphoma cell line where c-Myc levels are controlled by tetracycline, HIF-1a cooperates with, rather than antagonizes, c-Myc activities to enhance the expression of shared target genes including HK2 (encoding hexokinase 2), PDK1 (encoding pyruvate dehydrogenase kinase isozyme 1), and VEGFA (Figure 4b) . 53 HK2 catalyzes ATP-dependent phosphorylation of glucose to form glucose-6-phosphate in the first step of glycolysis, whereas PDK1 inhibits mitochondrial respiration by inactivating pyruvate dehydrogenase, which converts pyruvate to acetyl-CoA. It is interesting to note that although coexpression of HIF-1a and c-Myc enhances glucose metabolism, HK2 is the only glycolytic gene to be upregulated in this system. The expression of LDHA, another glycolytic gene best known to be responsive to HIF-1a or c-Myc, is not further enhanced by the two. Consistent with previous reports that the PDK1 gene is a target of HIF-1a, 54 ,55 c-Myc augments PKD1 expression in the presence of HIF-1a for lactate production. In addition, HIF1a and c-Myc also cooperate to activate the VEGFA gene. Such collaboration is associated with discrete and/or overlapping binding of HIF-1a and c-Myc to the target gene promoters. It remains unclear, however, what determines the interaction and/or cooperation between HIF-1a and c-Myc in the promoters of these common target genes. Whether such collaboration occurs for enhanced gene expression in other c-Myc deregulated tumor cells is yet to be determined. Furthermore, biochemical characterization of additional interacting proteins may help reconcile the differences between cooperative and antagonistic effects (discussed above) of HIF-1a on c-Myc. 
